<DOC>
	<DOC>NCT01919047</DOC>
	<brief_summary>This study is to determine the following information. 1. The occurrence of adverse drug reactions in clinical settings. 2. Factors potentially impacting safety, effectiveness, and other aspects.</brief_summary>
	<brief_title>Drug Use-Results Survey of Betanis Tablets in Japan</brief_title>
	<detailed_description>This survey aims to determine the following information and the need for conducting specified drug use-results surveys and post-marketing clinical studies in patients using Betanis (generic name: mirabegron): 1. The occurrence of adverse drug reactions in clinical settings. 2. Factors potentially impacting safety, effectiveness, and other aspects. Items of Particular Interest: - Safety and effectiveness in patients with hepatic impairment and patients with renal impairment. - Safety and effectiveness when mirabegron is used concomitantly with other drugs (α1 blockers, anticholinergic agents, 5α reductase inhibitors, drugs with a potent CYP3A4-inhibiting effect, drugs with a CYP3A4-inducing effect, drugs metabolized primarily by CYP2D6, and other frequently used drugs). - The occurrence of cardiovascular adverse events. - The occurrence of adverse events related to increased intraocular pressure. - The occurrence of urinary retention</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patients who received mirabegron for the first time for the treatment of urinary urgency, daytime frequency, and urgency incontinence associated with overactive bladder.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>overactive bladder</keyword>
	<keyword>mirabegron</keyword>
	<keyword>occurrence of adverse events</keyword>
	<keyword>Overactive Bladder Symptom Score</keyword>
</DOC>